Back Bay Life Science Advisors’ Post

📢 We're pleased to announce that we have advised GSK on their strategic alliance with Muna Therapeutics to accelerate the development of new treatments for Alzheimer’s disease. The research collaboration will leverage Muna’s innovative MiND-MAP platform to identify and validate novel drug targets. Under the agreement, Muna will receive an upfront payment from GSK of €33.5 million, and will be eligible to receive up to €140 million per target in milestone payments, as well as royalties on sales.   Our team was led by intellectual property partner and healthcare and life sciences specialist, Lydia Torne, who was supported by supervising associate James Agnew.   Read More: https://lnkd.in/eTwH_2K4

Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC Therapeutics, Inc.. Huntington’s disease is a condition that has long frustrated drugmakers. Novartis itself has previously tried without success to develop a transformative treatment. Read more about the deal and PTC's therapy: https://trib.al/0tYDtx6

In a remarkable turn of events, Clarity Pharmaceuticals Ltd has seen its shares soar by over 200% in the past six months on the ASX All Ordinaries Index, hitting a new all-time high. 🚀 This surge is no coincidence - it follows groundbreaking results from their copper therapy treatment for advanced prostate cancer, which catapulted shares from $1.06 to an impressive $3.31. The clinical and financial communities are abuzz as the company reported the first patient to complete two treatment cycles showing a 'complete response', undetectable PSA levels for nearly six months - leading to a 26.4% hike in share price recently. Such clinical success has spurred optimism among investors, with experts noting the company's undervaluation given its robust potential. Analysts and investors alike are keenly watching Clarity Pharmaceuticals Ltd, as it stands on the cusp of potentially transformative growth and value realization. 🌟 The trajectory ahead for Clarity Pharmaceuticals seems promising, teeming with opportunities for continued development. As the healthcare sector evolves, treatments like those offered by Clarity Pharmaceuticals are critical and their innovative approach could make significant strides in patient care. For those interested in the crossroads of biopharmaceutical innovation and investment opportunity, the rise of Clarity Pharmaceuticals is a story to follow closely. 💡 With much anticipation for what's to come, one thing is clear: they've become a signal to the market of the potential within therapy treatments. Stay tuned to see just how high Clarity Pharmaceuticals can go! For a full overview of their impressive market performance, click on the link: https://lnkd.in/g-5kFZJA #Biopharmaceuticals #Investment #HealthcareInnovation #StockMarket #ProstateCancer #TherapyTreatments #ASX #MarketSurge

Check out our team's work in the latest issue of Pharma Focus Europe Carl Schoellhammer, Aditi Ghalsasi, and Cassidy Humphreys share their perspectives and analysis on the evolution of #mRNA therapeutics from recent advances, barriers and challenges, to charting a path forward. Link to digital magazine here: https://lnkd.in/gQUdzfZb #advancedtherapies #precisionmedicine

Biosimilar Buzz: Top 5 News Stories This Week! This week's top stories: 5. Positive news! Biosimilars for psoriasis show promise. 4. Industry layoffs and a new oncology biosimilar on the horizon. 3. Mergers, partnerships, and new biosimilars in development! 2. New policies needed to boost biosimilar use in Europe? 1. President Biden's budget proposal could impact biosimilars! https://lnkd.in/eVvd3ir6

Biopharma investors remain cautiously optimistic about the remainder of 2024 despite renewed headwinds in recent months. That’s according to William Blair’s midyear investor survey, taken after capital market activity slowed but public financing remained robust in Q2. Areas of investor interest largely remained constant as I&I/oncology and ADCs/radiopharmaceuticals remain the therapeutic areas and modalities, respectively, with greatest enthusiasm. William Blair’s Biopharma team shares perspectives in the Quarterly Rx: Q2 2024 U.S. Biopharma Recap. Download your copy: https://lnkd.in/gDgWhUZq

Kairos Pharma Ltd. (NYSE: KAPA) today announced its approval to dual list its shares on Upstream. Trading will become available on Upstream November 26th at 10:00 am ET under the ticker symbol ‘KAPA’. The dual listing on Upstream is designed to provide Kairos Pharma the opportunity to access a global investor base outside the U.S., unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in Kairos Pharma. Dr. John Yu, CEO of Kairos Pharma, commented, “Building shareholder value is an ongoing goal of Kairos. We believe a dual listing on Upstream’s next generation market greatly supports this goal as we continue to expand our lead drug ENV105 to several widespread cancers and to advance our therapeutics through clinical testing and commercialization.” Press Release: https://lnkd.in/gsZ8s2Jm -- Disclaimers: U.S. or Canadian persons may not deposit, buy, or sell securities on Upstream: https://lnkd.in/ehaxqkXV

Cryopyrin-Associated Periodic Syndrome Pipeline Status 2024: Clinical Trials Overview and Key Companies involved by DelveInsight | Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cryopyrin-Associated Periodic Syndrome pipeline constitutes 4+ key companies continuously working towards developing 4+ Cryopyrin-Associated Periodic Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Novartis pays PTC $1B upfront for midphase Huntington's program 💰🔬 Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping the biotech bounce quickly back from disappointing data on another program. Wow, that's a huge move for PTC Therapeutics. $1 billion upfront definitely gives them a solid boost after the setback! Link in the comments for the full story. 🌐

What's In The Vial?! A [Brief] Meditation On Control Strategy Gregory Troiano from Sanofi and April Sena from Life Edit Therapeutics addressed an audience question on whether the crucial aspect lies in the contents of the vial or the production process itself. Watch the clip (2:27): https://lnkd.in/eYDrZqAw #AdvancingRNA #rawmaterials #mrna #supplychain